Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 901–1,000 of 1,000
Tenenbaum, J. D., Shah, N. H., & Altman, R. B. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4474-8_25 · Cited by 8
Computing Drug-Drug Similarity from Patient-Centric Data
Asiri, Y. (2023) · Bioengineering · doi:10.3390/bioengineering10020182 · Cited by 6
“In pharmaceutical drug development, in particular, DDS has successfully applied for drug repositioning [4,5], drug-drug interaction prediction [6,7], drug target identification [3], and drug side-effects prediction [7].”
BackgroundStructure‐Based De Novo Drug Design
Reddy, A. S., Chen, L., & Zhang, S. (2013) · Wiley eBooks · doi:10.1002/9783527677016.ch4 · Cited by 6
Interaction network among functional drug groups
Lee, M., Park, K., & Kim, D. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-s3-s4 · Cited by 6
“Recently, various drug-related properties including therapeutic target, off-target, activity, toxicity, pharmacokinetic properties and side effect have been successfully described by some elegant methods such as analysis of chemical structures [1], docking simulation [2-4], chemical-genetic profile [5-7], connectivity…”
MethodPrediction of Drugs Target Groups Based on ChEBI Ontology
Gao, Y., Chen, L., Huang, G., Zhang, T., Feng, K., Li, H., & Jiang, Y. (2013) · BioMed Research International · doi:10.1155/2013/132724 · Cited by 6
“Many efforts have been made to identify drugs target proteins in the past few years, such as docking simulations [2, 3], literature text mining [4], combination of chemical structure and protein structural information or functional information [5–8], side effect similarity [9], and so forth.”
Discovering second-order sub-structure associations in drug molecules for side-effect prediction
Hu, P., Chan, K. C. C., Hu, L., & Leung, H. (2017) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2017.8218013 · Cited by 6
“And, [12] used SEs similarities to discover the relations between SEs and target proteins, a wide variety of data-driven methods have been developed.”
Molecular Similarity in Computational Toxicology
Floris, M., & Olla, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7899-1_7 · Cited by 6
Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance
Hauser, A. S., Kooistra, A. J., Sverrisdóttir, E., & Sessa, M. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1780208 · Cited by 6
Machine learning-based methods and novel data models to predict adverse drug reaction
Wang, J., Deng, Y., Shu, L., & Deng, L. (2020) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm49941.2020.9313093 · Cited by 6
Wan, J.-T., Jia, C., Dong, D.-H., Chen, Y.-G., Lin, Y.-C.-D., He, Y., Huang, H.-Y., & Huang, H.-D. (2025) · bioRxiv · doi:10.1093/bib/bbaf695 · Cited by 5
“With the de vel-opment of network-based methods, some studies leveraged drug and ADR similarity networks [21,22],linear neighborhood similarity [23], analysis of drug-target interactions and protein domains [24], or more complex network/domain information like NDDSA [25].”
Digital twin approaches for interpretable side effect prediction in drug discovery
Ecker, A., Szabó, G., Szalma, J., Fichó, E., Reguly, I. Z., & Csikász-Nagy, A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104637 · Cited by 7
Lin, H., Vogel, H., & Zhang, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073142 · Cited by 5
Systems and Network Pharmacology Strategies for Pancreatic Ductal Adenocarcinoma Therapy
Muqbil, I., Azmi, A. S., & Mohammad, R. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-408103-1.00018-2 · Cited by 5
Knott, S. D., Matten, S. R., & Staff, S. (2013) · Cited by 5
Predicting drug synergy using a network propagation inspired machine learning framework
Jin, Q., Zhang, X., Huo, D., Xie, H., Zhang, D., Liu, L., Zhao, Y., & Chen, X. (2024) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad056 · Cited by 5
Shin, Y.-Z., Yum, Y. A., Bae, E. S., Jarhad, D. B., Aswar, V. R., Tripathi, S., Kwon, E., Kim, Y.-J., Kim, M., Lee, S. K., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118135 · Cited by 5
McGarry, K., Slater, N., & Amanning, A. (2015) · Sunderland Repository (University of Sunderland) · Cited by 5
Leveraging systems biology approaches in clinical pharmacology
Melas, I. N., Kretsos, K., & Alexopoulos, L. G. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1859 · Cited by 6
“[47] used drug”
BackgroundAn In Silico Model for Interpreting Polypharmacology in Drug–Target Networks
Takigawa, I., Tsuda, K., & Mamitsuka, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-342-8_5 · Cited by 5
Applications of systems approaches in the study of rheumatic diseases
Kim, K., Lee, S., & Kim, W. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.2.148 · Cited by 5
“This approach may be useful for predicting the adverse effects of drugs, repurposing old drugs, and designing new drugs with maximal efficacy and minimal adverse effects [19,20,86].”
BackgroundZhou, K., Zhang, S., Meng, X., Luo, Q., Wang, Y., Ding, K., Feng, Y., Chen, M., Cohen, K. B., & Xia, J. (2018) · Workshop on Biomedical Language Processing (BioNLP) · doi:10.18653/v1/w18-2321 · Cited by 5
“Andreas et al., (Andreas et al., 2007) used chemical structure information to infer the drug-target pair, while Monica et al., (Monica et al., 2008) used phenotypic side effect similarities to make the inference.”
BackgroundMethodUsing Snomed to recognize and index chemical and drug mentions.
Úbeda, P. L., Galiano, M. C. D., López, L. A. U., & Martín, M. (2019) · Workshop on BioNLP Open Shared Tasks (BioNLP-OST) · doi:10.18653/v1/d19-5718 · Cited by 5
“At present, it has referred to kinds of domains, such as protein (Liu et al., 2005; Mitsumori et al., 2005; Tsuruoka and Tsujii, 2003), gene (Liu et al., 2005; Leser and Hakenberg, 2005) or drug (Campillos et al., 2008).”
BackgroundPERBANDINGAN BEBERAPA METODE KLASIFIKASI DALAM MEMPREDIKSI INTERAKSI FARMAKODINAMIK
Hasnita, H., Afendi, F. M., & Fitrianto, A. (2019) · Indonesian Journal of Statistics and Its Applications · doi:10.29244/ijsa.v4i1.328 · Cited by 5
Semantic Breakthrough in Drug Discovery
Chen, B., Wang, H., Ding, Y., & Wild, D. J. (2014) · Synthesis lectures on the semantic web · doi:10.2200/s00600ed1v01y201409web009 · Cited by 6
Present and future challenges in therapeutic designing using computational approaches
Prasad, S., Srivastava, A., Singh, N., Singh, H., Saluja, R., Kumar, A., Yadav, N., & Qidwai, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00020-0 · Cited by 5
“Analogous homogenous or bi-partite network models have been included using phenotype data such as side-effect (Campillos et al., 2008; Mizutani et al., 2012; Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection Ye et al., 2014), transcriptional…”
In Silico Prediction of Drug Side Effects
Keiser, M. J. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch02 · Cited by 5
A Machine Learning Approach to Explain Drug Selectivity to Soluble and Membrane Protein Targets
Freyhult, E., Gustafsson, M. G., & Strömbergsson, H. (2015) · Molecular Informatics · doi:10.1002/minf.201400121 · Cited by 6
Global view of a drug-sensitivity gene network
Yang, H., Zhang, Y., Wang, J., Wu, T., Liu, S., Xu, Y., & Shang, D. (2017) · Oncotarget · doi:10.18632/oncotarget.23229 · Cited by 5
BioHackathon 2015: Semantics of data for life sciences and reproducible research
Vos, R. A., Katayama, T., Mishima, H., Kawano, S., Kawashima, S., Kim, J.-D., Moriya, Y., Tokimatsu, T., Yamaguchi, A., Yamamoto, Y., et al. (2020) · F1000Research · doi:10.12688/f1000research.18236.1 · Cited by 5
Analysis of Drug Repositioning and Prediction Techniques: A Concise Review
He, S., Liu, X., Ye, X., & Sakurai, T. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220317164016 · Cited by 5
Proposal to Consider Chemical/Physical Microenvironment as a New Therapeutic Off-Target Approach
Giuliani, A., & Fais, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102084 · Cited by 5
“Many of the purposes behind newly treated microenvironmental acidity come from the new paradigm of using the off-targeting of old drugs [5], but some interesting and novel approaches to finding new anti-cancer drugs in the panel of available drugs have recently been proposed [50], thus opening a promising future for t…”
BackgroundMultimodal multi-task deep neural network framework for kinase–target prediction
Hua, Y., Luo, L., Qiu, H., Huang, D., Zhao, Y., Liu, H., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10565-8 · Cited by 5
“However, there are also cases where drug compounds interacting with other unexpected proteins can produce novel therapeutic effects [4, 5].”
BackgroundYu, Z., Wu, Z., Zhou, M., Chen, L., Li, W., Liu, G., & Tang, Y. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107831 · Cited by 5
Data Mining Using Ligand Profiling and Target Fishing
Bryant, S. D., & Langer, T. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527655984.ch11 · Cited by 5
Application of Machine Learning in Knowledge Discovery for Pharmaceutical Drug-drug Interactions
Herrero-Zazo, M., Lille, M., & Barlow, D. J. (2016) · Research Portal (King's College London) · Cited by 7
Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions
La, M. K., Sedykh, A., Fourches, D., Muratov, E. N., & Tropsha, A. (2018) · Drug Safety · doi:10.1007/s40264-018-0688-5 · Cited by 5
“[17] used side effect profile similarity to impute new pharmacological targets for known drugs, while Lounkine et al.”
A Comprehensive Integrated Drug Similarity Resource for In-Silico Drug Repositioning and BeyondPreprint
Azad, A., Dinarvand, M., Nematollahi, A., Swift, J., Lutze-Mann, L. H., & Vafaee, F. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12376505 · Cited by 5
Wei, X., Zhu, T., Yip, H. F., Fu, X., Jiang, D., Deng, Y., Lu, A., & Cao, D. (2024) · Chemical Science · doi:10.1039/d4sc03580a · Cited by 4
Advances in Computational Drug Repurposing, Driver Genes, and Therapeutics in Lung Adenocarcinoma
Nematzadeh, S., & Karaul, A. (2025) · Biomolecules · doi:10.3390/biom15101373 · Cited by 4
“Modern pipelines extend this with pharmacovigilance signal processing (FAERS) and reporting standards (READUS-PV) to curb bias [11,144,145].”
Xia, Y., Pan, X., & Shen, H. (2024) · Structure · doi:10.1016/j.str.2024.02.004 · Cited by 4
Köse, U., Deperlioğlu, Ö., Küçüksille, E. U., & TURAN, G. (2024) · International Conference on Inventive Computation Technologies (ICICT) · doi:10.1109/icict60155.2024.10544998 · Cited by 4
“…[34] 2739 approved small molecule drugs, 1575 approved proteins, peptides, vaccines and allergenics, 134 nutraceuticals and 15,444 drug data SIDER [35] 139,756 drug-side effect pairs, 1430 drugs and 5868 side effect data PubChem [36] Data set containing a wide range of structure and interaction…”
BackgroundBoyd, S. S., Robarts, D. R., Nguyen, K., Villar, M. T., Alghusen, I. M., Kotulkar, M., Denson, A. R., Fedosyuk, H., Whelan, S. A., Lee, N. C. Y., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102060 · Cited by 5
Sama‐ae, I., Muengthongon, P., Tohlaeh, A., Rukhachan, W., Kiattikul, P., Samaeng, F., Mitklin, A., Rahman, M. A., Tedasen, A., Kwankaew, P., et al. (2025) · Scientifica · doi:10.1155/sci5/8838031 · Cited by 7
Efficient Data Mining Algorithms for Screening Potential Proteins of Drug Target
Wang, Q., Huang, J., Feng, Y., & Fei, J. (2017) · Mathematical Problems in Engineering · doi:10.1155/2017/9852063 · Cited by 4
“Looking back to the previous methodologies of identification of drug target proteins (IDTPs), some specific biological hypotheses were required such as side-effect similarity [9], chemical structure, and genomic sequence information [10].”
BackgroundNetworks and Pathways in Systems Pharmacology
Bezerianos, A., Dragomir, A., & Balomenos, P. (2017) · SpringerBriefs in computer science · doi:10.1007/978-3-319-53868-6_2 · Cited by 4
Yamanishi, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8639-2_12 · Cited by 4
Polypharmacology in Old Drug Rediscovery: Drug Repurposing
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_13 · Cited by 7
General Strategies for Rational Design and Discovery of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_18 · Cited by 6
Wang, K., Hu, J., & Zhang, X. (2023) · Lecture notes in computer science · doi:10.1007/978-981-99-4749-2_21 · Cited by 5
Nanocomposites Based on Upconversion Nanoparticles
Bastani, S., Kandeloos, A. J., Jalili, M., & Ghahari, M. (2023) · Progress in optical science and photonics · doi:10.1007/978-981-99-3913-8_6 · Cited by 4
Protein-Protein Interaction Networks: Structures, Evolution, and Application to Drug Design
Hase, T., & Niimura, Y. (2012) · IntechOpen eBooks · doi:10.5772/36665 · Cited by 4
A Benchmark Dataset for Computational Drug Repositioning
Kissa, M., & Tsatsaronis, G. (2015) · Biomedical Data Journal · doi:10.11610/bmdj.01202 · Cited by 4
Methods in literature-based drug discovery
Baker, N. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/1tdd-3k21 · Cited by 6
Computational approaches for the study of the role of small molecules in diseases
Campillos, M. (2016) · Perspectives in Science · doi:10.1016/j.pisc.2016.08.001 · Cited by 4
Self-citationSteroids-specific target library for steroids target prediction
Dang, X., Liu, Z., Zhou, Y., Chen, P., Liu, J., Yao, X., & Lei, B. (2018) · Steroids · doi:10.1016/j.steroids.2018.10.002 · Cited by 5
“Side-effect-based methods use phenotypic side-effect similarities to infer whether two drugs share one target which can derive target predictions from adverse effects [43].”
Efficient Gaussian sample specific network marker discovery and drug enrichment analysis validation
Liu, W., Du, Y., Fang, G., Kou, Z., Wang, X., & Han, H. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107139 · Cited by 4
[Drug-target protein interaction prediction based on AdaBoost algorithm].
Gu, W., Xie, X., He, Y., & Zhang, Z. (2018) · PubMed Central · doi:10.7507/1001-5515.201802026 · Cited by 4
Integrating bioassay data for improved prediction of drug-target interaction
Dai, W., Li, L., & Guo, D. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106455 · Cited by 4
Text Mining Gene Selection to Understand Pathological Phenotype Using Biological Big Data
Desterke, C., Lorenzo, H. K., & Candelier, J. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.bioinformatics.2021.ch1 · Cited by 4
Kreir, M., Putri, D., Tekle, F. B., Pibiri, F., d’Ydewalle, C. V. O., Ammel, K. V., Geys, H., Teisman, A. C. H., Gallacher, D. J., & Lu, H. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1308547 · Cited by 5
Representation Learning of Drug and Disease Terms for Drug Repositioning
Manchanda, S., & Anand, A. (2017) · IEEE International Conference on Cybernetics (CYBCONF) · doi:10.1109/cybconf.2017.7985802 · Cited by 5
“Studies [16] show that drugs sharing off targets might also share on targets.”
BackgroundSystems Pharmacology for the Study of Anticancer Drugs: Promises and Challenges
Liu, J. (2015) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.1000140 · Cited by 4
“Ultimately, network analysis could provide global views on drug-target relationships and intertwining interactions among cellular pathways in physiological and pathological processes [4-6].”
BackgroundNon-Specificity of Drug-Target Interactions – Consequences for Drug Discovery
Maggiora, G. M., & Gokhale, V. M. (2016) · ACS symposium series · doi:10.1021/bk-2016-1222.ch007 · Cited by 5
Polypharmacology in Drug Discovery
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527674381.ch1 · Cited by 4
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon‐14
Kang, J., Lee, J. Y., Park, J. H., & Chang, D. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3830 · Cited by 4
Drug Repurposing in Oncotherapeutics
Patel, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92302 · Cited by 4
Challenges for the Optimization of Drug Therapy in the Treatment of Cancer
Carels, N., Conforte, A. J., Lima, C. R., & da Silva, F. A. B. (2020) · Computational biology · doi:10.1007/978-3-030-51862-2_8 · Cited by 4
The state of the art in text mining and natural language processing for pharmacogenomics
Coulet, A., Cohen, K. B., & Altman, R. B. (2012) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2012.08.001 · Cited by 4
Should network biology be used for drug discovery?
Martínez-Jiménez, F., & Martí-Renom, M. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1236786 · Cited by 4
Similarity based learning method for drug target interaction prediction
Bharadwaja, A. (2014) · Cited by 4
Wang, Y., Chen, S., Deng, N.-Y., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/annotation/fe02e998-6a38-4fd7-9df6-241bc4d0f267 · Cited by 5
De novo Molecular Design using Deep Learning
Nguyen‐Vo, T. (2024) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.25044362 · Cited by 7
Review on QSAR using Anticancer Drug
Ahirwar, H., Kurmi, G., Khan, R., Khare, B., Jain, A., Jain, P. K., & Thakur, B. S. (2022) · Asian Journal of Dental and Health Sciences · doi:10.22270/ajdhs.v2i4.27 · Cited by 3
Rymbai, E., Sugumar, D., Krishnamurthy, P. T., Selvaraj, D., Vasu, S., Priya, S., & Saravanan, J. (2023) · Drug Research · doi:10.1055/a-2011-5662 · Cited by 3
“The previous study has shown that drugs that share a higher number of similar side effects between them are expect ed to act on common targets and produce similar pharmacologi cal effects [7].”
BackgroundDíaz-Santiago, E., Moya‐García, A. A., Pérez-García, J., Yahyaoui, R., Orengo, C. A., Pazos, F., Perkins, J. R., & Ranea, J. A. G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1470931 · Cited by 3
Integration of diverse bioactivity data into the Chemical Checker compound universe
Comajuncosa-Creus, A., Bertoni, M., Duran‐Frigola, M., Fernández‐Torras, A., Guitart-Pla, O., Kurzawa, N., Locatelli, M., Martins, Y., Pareja-Lorente, E., Rojas-Granado, G., et al. (2025) · Nature Protocols · doi:10.1038/s41596-025-01167-3 · Cited by 4
Tricyclic Isatin Derivatives as Anti-Inflammatory Compounds with High Kinase Binding Affinity
Uvarov, A. V., Schepetkin, I. A., Quinn, M. T., & Khlebnikov, А. I. (2025) · Molecules · doi:10.3390/molecules30142914 · Cited by 3
“Off-target effects are typically unwanted and may be harmful, but in some cases, they have proven to be beneficial, resulting in new and unexpected uses for drugs [19].”
PersADE: a database of personalized adverse drug events and their underlying molecular mechanisms
Yu, Z., Wang, Y., Zhang, Y., Zhou, Y., Hu, X., Shen, L., Ni, C., Xing, P., Huang, F., Fu, T., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1095 · Cited by 4
“…ADEs) can offer valuable insights [ 4 –6 ], which has been adopted in the identification of novel therapeutic targets for various diseases [ 7 , 8 ], the successful drug repurposing exemplified by sildenafil from angina treatment to erectile dysfunction therapy [ 9 , 10 ], the precision dosing…”
Compound annotation with real time cellular activity profiles to improve drug discovery
Ye, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1143460 · Cited by 3
“[22,29,55] Package inserts are publicly available from several sources including the FDA, public websites, and the manufacturers.”
BackgroundSimilarity between semantic description sets: addressing needs beyond data integration
Vision, T., Blake, J. A., Lapp, H., Mabee, P., & Westerfield, M. (2011) · Cited by 3
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Development
Dash, R., Munni, Y. A., Mitra, S., Dash, N., & Moon, I. S. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_15 · Cited by 5
PHARMACOVIGILANCE: A PARADIGM SHIFT FROM CARE TO SAFETY
Ali, H., Zafar, F., Hasnain, H., Ahmed, S., Mallick, N., Tariq, A., Saleem, S., & Zubair, S. (2016) · The Professional Medical Journal · doi:10.29309/tpmj/2016.23.11.1751 · Cited by 4
Drug Target Identification Based on Flux Balance Analysis of Metabolic Networks
Li, Z., Wang, R., & Xia, Y. (2010) · Cited by 3
Zheng, Y., Meng, X., Zweigenbaum, P., Chen, L., & Xia, J. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-1105-4 · Cited by 3
Software Architectures and Efficient Data Sharing for Promoting Continuous Drug Re-purposing
Juric, R., Fuh, C. C., & Kim, I. (2021) · Hawaii International Conference on System Sciences (HICSS) · doi:10.24251/hicss.2021.450 · Cited by 3
“The idea of exploiting the drug-target identification, using side-effect similarity, as described in [48], may have an impact on the process of discovering new purposes of existing drugs.”
BackgroundAier, I., & Varadwaj, P. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822312-3.00006-0 · Cited by 5
Genome-wide discovery of hidden genes mediating known drug-disease association using KDDANet
Yu, H., Lu, L., Chen, M., Li, C., & Zhang, J. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00216-6 · Cited by 4
In silico drug repositioning based on integrated drug targets and canonical correlation analysis
Chen, H., Zhang, Z., & Zhang, J. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01203-1 · Cited by 3
“Previous research efforts were mainly made on the first type of molecular targets [9–12].”
MethodZhang, J., & Xie, M. (2022) · IEEE Access · doi:10.1109/access.2022.3199667 · Cited by 3
“Campillos et al. [3] introduced a method using drug side-effect similarity to infer the possibility that a drug interacts with a target.”
MethodHypergraph Computation for Medical and Biological Applications
Dai, Q., & Gao, Y. (2023) · Artificial intelligence: foundations, theory, and algorithms/Artificial intelligence: Foundations, theory, and algorithms · doi:10.1007/978-981-99-0185-2_10 · Cited by 3
Application of artificial intelligence in pharmaceutical development
Mourelatou, E. A., Iosif, E., Galatou, E., Sarigiannis, Y. M., Vlasiou, M. C., Zacharia, L. C., & Petrou, C. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91816-9.00009-6 · Cited by 4
An Overview of Artificial Intelligence (AI) In Drug Delivery and Development
Mutha, R. E., Bagul, V. S., Tade, R. S., & Vinchurkar, K. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305753124010004 · Cited by 9
Crunkhorn, S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2670 · Cited by 3
Christadore, L. M., Pham, L., Kolaczyk, E. D., & Schaus, S. E. (2014) · BMC Systems Biology · doi:10.1186/1752-0509-8-7 · Cited by 3
“Supervised learning methods like support vector machines have also been widely used to develop statistical methods that predict drug-protein interactions [18-22].”
An integrated workflow for proteome-wide off-target identification and polypharmacology drug design
Evangelidis, T., Bourne, P. E., Xie, L., & Xie, L. (2012) · IEEE International Conference on Bioinformatics and Biomedicine Workshops (BIBMW) · doi:10.1109/bibmw.2012.6470348 · Cited by 3
“[11] M.”
BackgroundAn integrated workflow for proteome-wide off-target identification and polypharmacology drug design
Evangelidis, T., & Xie, L. (2014) · Tsinghua Science & Technology · doi:10.1109/tst.2014.6838198 · Cited by 3
“Key words: drug discovery; structural proteomics; polypharmacology; off-target; systems biology”
BackgroundAn Integrative Approach for Discovery of New Uses of Existing Drugs
Li, J., & Lu, Z. (2015) · Data Science Journal · doi:10.5334/dsj-2015-009 · Cited by 3
“For instance, Campillos et al. (2008) used drug adverse effects to identify novel drug-target relationships (off-target interactions), which further connected drugs to new uses.”
BackgroundHamamoto, T., Serizawa, A., Ohtsuki, K., Kawakami, J., & Sato, K. (2014) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00145 · Cited by 3
Pham, D., Le, B.-K., Ho, T.-B., & Le, L. (2016) · RIVF International Conference on Computing and Communication Technologies (RIVF) · doi:10.1109/rivf.2016.7800301 · Cited by 4
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.